Patient-centered health intelligence company saw its post-money valuation go above $1 billion after closing an oversubscribed $121 million Series C financing round, the company announced Wednesday.
Subscribe to the Crunchbase Daily
Stamford, Connecticut-based Sema4 is a 2017 Mount Sinai Health System spinoff using its Centrellis health intelligence platform to improve patient outcomes by providing science-driven diagnosis, treatment and prevention in the initial areas of reproductive health and oncology.
led the oversubscribed round that also included new investors and , the company said in a written statement. The Series C comes less than a year after Sema4 raised its Series B—its first round of external funding at just over $120 million from , , , and , all companies that also participated in its Series C, according to the company.
“This investment is exciting for the significant financial resources it provides Sema4 for our continued rapid growth and accelerated investment, and also for the world-renowned partners it brings to our team,” said , founder and CEO of Sema4, in a written statement. “
As part of the investment, Deerfield Partner , M.D., joined Sema4’s board of directors.
In April, Sema4 launched efforts for high-risk individuals and medical personnel across Connecticut and New York. In June, that the company expanded its relationship with the State of Connecticut to provide COVID-19 testing to residents, as well as state employees and first responders.
Illustration:
Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.


67.1K Followers